Therapeutic effect of erythromycin on influenza virus-induced lung injury in mice
Identifieur interne : 001B19 ( Main/Exploration ); précédent : 001B18; suivant : 001B20Therapeutic effect of erythromycin on influenza virus-induced lung injury in mice
Auteurs : K. Sato [Japon] ; M. Suga [Japon] ; T. Akaike [Japon] ; S. Fujii [Japon] ; H. Muranaka [Japon] ; T. Doi [Japon] ; H. Maeda [Japon] ; M. Ando [Japon]Source :
- American journal of respiratory and critical care medicine [ 1073-449X ] ; 1998.
Descripteurs français
- KwdFr :
- Animaux, Anti-inflammatoires (administration et posologie), Anti-inflammatoires (usage thérapeutique), Antibactériens (administration et posologie), Antibactériens (usage thérapeutique), Cause de décès, Infections à Orthomyxoviridae (anatomopathologie), Infections à Orthomyxoviridae (enzymologie), Infections à Orthomyxoviridae (traitement médicamenteux), Injections péritoneales, Interféron gamma (), Interféron gamma (biosynthèse), Lignées consanguines de souris, Liquide de lavage bronchoalvéolaire (cytologie), Lymphocytes (), Lymphocytes (anatomopathologie), Macrophages (), Macrophages (anatomopathologie), Monocytes (), Monocytes (anatomopathologie), Monoxyde d'azote (biosynthèse), Monoxyde d'azote (effets indésirables), Mâle, Nitrates (sang), Nitric oxide synthase (), Nitrites (sang), Pneumopathie virale (anatomopathologie), Pneumopathie virale (enzymologie), Pneumopathie virale (traitement médicamenteux), Poids du corps, Poumon (), Poumon (anatomopathologie), Poumon (enzymologie), Poumon (virologie), Radicaux libres (effets indésirables), Relation dose-effet des médicaments, Souris, Superoxydes (effets indésirables), Taux de survie, Virus de la grippe A (), Érythromycine (administration et posologie), Érythromycine (usage thérapeutique).
- MESH :
- administration et posologie : Anti-inflammatoires, Antibactériens, Érythromycine.
- anatomopathologie : Infections à Orthomyxoviridae, Lymphocytes, Macrophages, Monocytes, Pneumopathie virale, Poumon.
- biosynthèse : Interféron gamma, Monoxyde d'azote.
- cytologie : Liquide de lavage bronchoalvéolaire.
- effets indésirables : Monoxyde d'azote, Radicaux libres, Superoxydes.
- enzymologie : Infections à Orthomyxoviridae, Pneumopathie virale, Poumon.
- sang : Nitrates, Nitrites.
- traitement médicamenteux : Infections à Orthomyxoviridae, Pneumopathie virale.
- usage thérapeutique : Anti-inflammatoires, Antibactériens, Érythromycine.
- virologie : Poumon.
- Pascal (Inist)
- Animaux, Cause de décès, Injections péritoneales, Interféron gamma, Lignées consanguines de souris, Lymphocytes, Macrophages, Monocytes, Mâle, Nitric oxide synthase, Pneumonie, Influenzavirus, Erythromycine, Poids du corps, Poumon, Relation dose-effet des médicaments, Souris, Taux de survie, Virus de la grippe A, Voie intrapéritonéale, Antiinflammatoire, Exploration, Mécanisme action, Survie, Souris, Animal.
English descriptors
- KwdEn :
- Animal, Animals, Anti-Bacterial Agents (administration & dosage), Anti-Bacterial Agents (therapeutic use), Anti-Inflammatory Agents (administration & dosage), Anti-Inflammatory Agents (therapeutic use), Antiinflammatory agent, Body Weight, Bronchoalveolar Lavage Fluid (cytology), Cause of Death, Dose-Response Relationship, Drug, Erythromycin, Erythromycin (administration & dosage), Erythromycin (therapeutic use), Exploration, Free Radicals (adverse effects), Influenza A virus (drug effects), Influenzavirus, Injections, Intraperitoneal, Interferon-gamma (biosynthesis), Interferon-gamma (drug effects), Intraperitoneal administration, Lung (drug effects), Lung (enzymology), Lung (pathology), Lung (virology), Lymphocytes (drug effects), Lymphocytes (pathology), Macrophages (drug effects), Macrophages (pathology), Male, Mechanism of action, Mice, Mice, Inbred Strains, Monocytes (drug effects), Monocytes (pathology), Mouse, Nitrates (blood), Nitric Oxide (adverse effects), Nitric Oxide (biosynthesis), Nitric Oxide Synthase (drug effects), Nitrites (blood), Orthomyxoviridae Infections (drug therapy), Orthomyxoviridae Infections (enzymology), Orthomyxoviridae Infections (pathology), Pneumonia, Pneumonia, Viral (drug therapy), Pneumonia, Viral (enzymology), Pneumonia, Viral (pathology), Superoxides (adverse effects), Survival, Survival Rate.
- MESH :
- chemical , administration & dosage : Anti-Bacterial Agents, Anti-Inflammatory Agents, Erythromycin.
- chemical , adverse effects : Free Radicals, Nitric Oxide, Superoxides.
- chemical , biosynthesis : Interferon-gamma, Nitric Oxide.
- chemical , blood : Nitrates, Nitrites.
- chemical , drug effects : Interferon-gamma, Nitric Oxide Synthase.
- chemical , therapeutic use : Anti-Bacterial Agents, Anti-Inflammatory Agents, Erythromycin.
- cytology : Bronchoalveolar Lavage Fluid.
- drug effects : Influenza A virus, Lung, Lymphocytes, Macrophages, Monocytes.
- drug therapy : Orthomyxoviridae Infections, Pneumonia, Viral.
- enzymology : Lung, Orthomyxoviridae Infections, Pneumonia, Viral.
- pathology : Lung, Lymphocytes, Macrophages, Monocytes, Orthomyxoviridae Infections, Pneumonia, Viral.
- virology : Lung.
- Animals, Body Weight, Cause of Death, Dose-Response Relationship, Drug, Injections, Intraperitoneal, Male, Mice, Mice, Inbred Strains, Survival Rate.
Abstract
Erythromycin (EM) is an antibiotic with potent antiinflammatory effects that is used for treating chronic lower respiratory tract infections. It has been shown that free radicals, such as the superoxide anion and nitric oxide (NO), are pathogenic molecules in viral disease. Much attention has been given to a critical role of NO in the pathologic events of various inflammatory diseases. In the present study, we evaluated the effects of EM on influenza-virus-induced pneumonia in mice infected with a lethal dose of influenza virus A/Kumamoto/Y5/67 (H2N2). The administration of EM at a dose of 3.3 mg/kg/d (intraperitoneally, from Days 1 to 6 after infection), significantly improved the survival rate of mice infected with influenza virus, and the survival rate of the virus-infected mice at Day 20 after infection increased in a dose-dependent fashion with EM administered to the animals, from 14% among controls to 42% among animals given EM at 1.0 mg/kg/d and 57% among those given EM at 3.3 mg/kg/d. The induction of interferon-γ (IFN-γ) in the mouse lung was inhibited by EM treatment on Day 6 after infection. Simultaneously, the number of inflammatory cells recovered in lung lavage fluid 6 d after virus infection was significantly reduced by the treatment with EM. The EM treatment resulted in a dose-dependent decrease in the level of nitrite/nitrate (metabolites of NO) in the serum and the NO synthase (NOS)-inducting potential in the lungs of the virus-infected mice. These results indicate that EM may have substantial therapeutic value for various acute inflammatory disorders such as influenza-virus-induced pneumonia, by inhibiting inflammatory-cell responses and suppressing NO overproduction in the lung.
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 000082
- to stream PascalFrancis, to step Curation: 000132
- to stream PascalFrancis, to step Checkpoint: 000077
- to stream Main, to step Merge: 001B75
- to stream PubMed, to step Corpus: 000386
- to stream PubMed, to step Curation: 000386
- to stream PubMed, to step Checkpoint: 000345
- to stream Ncbi, to step Merge: 001356
- to stream Ncbi, to step Curation: 001356
- to stream Ncbi, to step Checkpoint: 001356
- to stream Main, to step Merge: 001A91
- to stream Main, to step Curation: 001B19
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Therapeutic effect of erythromycin on influenza virus-induced lung injury in mice</title><author><name sortKey="Sato, K" sort="Sato, K" uniqKey="Sato K" first="K." last="Sato">K. Sato</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>First Department of Internal Medicine and Department of Microbiology, Kumamoto University School of Medicine</s1><s2>Kumamoto</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>Japon</country><wicri:noRegion>Kumamoto</wicri:noRegion></affiliation></author><author><name sortKey="Suga, M" sort="Suga, M" uniqKey="Suga M" first="M." last="Suga">M. Suga</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>First Department of Internal Medicine and Department of Microbiology, Kumamoto University School of Medicine</s1><s2>Kumamoto</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>Japon</country><wicri:noRegion>Kumamoto</wicri:noRegion></affiliation></author><author><name sortKey="Akaike, T" sort="Akaike, T" uniqKey="Akaike T" first="T." last="Akaike">T. Akaike</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>First Department of Internal Medicine and Department of Microbiology, Kumamoto University School of Medicine</s1><s2>Kumamoto</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>Japon</country><wicri:noRegion>Kumamoto</wicri:noRegion></affiliation></author><author><name sortKey="Fujii, S" sort="Fujii, S" uniqKey="Fujii S" first="S." last="Fujii">S. Fujii</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>First Department of Internal Medicine and Department of Microbiology, Kumamoto University School of Medicine</s1><s2>Kumamoto</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>Japon</country><wicri:noRegion>Kumamoto</wicri:noRegion></affiliation></author><author><name sortKey="Muranaka, H" sort="Muranaka, H" uniqKey="Muranaka H" first="H." last="Muranaka">H. Muranaka</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>First Department of Internal Medicine and Department of Microbiology, Kumamoto University School of Medicine</s1><s2>Kumamoto</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>Japon</country><wicri:noRegion>Kumamoto</wicri:noRegion></affiliation></author><author><name sortKey="Doi, T" sort="Doi, T" uniqKey="Doi T" first="T." last="Doi">T. Doi</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>First Department of Internal Medicine and Department of Microbiology, Kumamoto University School of Medicine</s1><s2>Kumamoto</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>Japon</country><wicri:noRegion>Kumamoto</wicri:noRegion></affiliation></author><author><name sortKey="Maeda, H" sort="Maeda, H" uniqKey="Maeda H" first="H." last="Maeda">H. Maeda</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>First Department of Internal Medicine and Department of Microbiology, Kumamoto University School of Medicine</s1><s2>Kumamoto</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>Japon</country><wicri:noRegion>Kumamoto</wicri:noRegion></affiliation></author><author><name sortKey="Ando, M" sort="Ando, M" uniqKey="Ando M" first="M." last="Ando">M. Ando</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>First Department of Internal Medicine and Department of Microbiology, Kumamoto University School of Medicine</s1><s2>Kumamoto</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>Japon</country><wicri:noRegion>Kumamoto</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">98-0174340</idno><date when="1998">1998</date><idno type="stanalyst">PASCAL 98-0174340 INIST</idno><idno type="RBID">Pascal:98-0174340</idno><idno type="wicri:Area/PascalFrancis/Corpus">000082</idno><idno type="wicri:Area/PascalFrancis/Curation">000132</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000077</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000077</idno><idno type="wicri:doubleKey">1073-449X:1998:Sato K:therapeutic:effect:of</idno><idno type="wicri:Area/Main/Merge">001B75</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:9517602</idno><idno type="wicri:Area/PubMed/Corpus">000386</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000386</idno><idno type="wicri:Area/PubMed/Curation">000386</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000386</idno><idno type="wicri:Area/PubMed/Checkpoint">000345</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000345</idno><idno type="wicri:Area/Ncbi/Merge">001356</idno><idno type="wicri:Area/Ncbi/Curation">001356</idno><idno type="wicri:Area/Ncbi/Checkpoint">001356</idno><idno type="wicri:doubleKey">1073-449X:1998:Sato K:therapeutic:effect:of</idno><idno type="wicri:Area/Main/Merge">001A91</idno><idno type="wicri:Area/Main/Curation">001B19</idno><idno type="wicri:Area/Main/Exploration">001B19</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Therapeutic effect of erythromycin on influenza virus-induced lung injury in mice</title><author><name sortKey="Sato, K" sort="Sato, K" uniqKey="Sato K" first="K." last="Sato">K. Sato</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>First Department of Internal Medicine and Department of Microbiology, Kumamoto University School of Medicine</s1><s2>Kumamoto</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>Japon</country><wicri:noRegion>Kumamoto</wicri:noRegion></affiliation></author><author><name sortKey="Suga, M" sort="Suga, M" uniqKey="Suga M" first="M." last="Suga">M. Suga</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>First Department of Internal Medicine and Department of Microbiology, Kumamoto University School of Medicine</s1><s2>Kumamoto</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>Japon</country><wicri:noRegion>Kumamoto</wicri:noRegion></affiliation></author><author><name sortKey="Akaike, T" sort="Akaike, T" uniqKey="Akaike T" first="T." last="Akaike">T. Akaike</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>First Department of Internal Medicine and Department of Microbiology, Kumamoto University School of Medicine</s1><s2>Kumamoto</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>Japon</country><wicri:noRegion>Kumamoto</wicri:noRegion></affiliation></author><author><name sortKey="Fujii, S" sort="Fujii, S" uniqKey="Fujii S" first="S." last="Fujii">S. Fujii</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>First Department of Internal Medicine and Department of Microbiology, Kumamoto University School of Medicine</s1><s2>Kumamoto</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>Japon</country><wicri:noRegion>Kumamoto</wicri:noRegion></affiliation></author><author><name sortKey="Muranaka, H" sort="Muranaka, H" uniqKey="Muranaka H" first="H." last="Muranaka">H. Muranaka</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>First Department of Internal Medicine and Department of Microbiology, Kumamoto University School of Medicine</s1><s2>Kumamoto</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>Japon</country><wicri:noRegion>Kumamoto</wicri:noRegion></affiliation></author><author><name sortKey="Doi, T" sort="Doi, T" uniqKey="Doi T" first="T." last="Doi">T. Doi</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>First Department of Internal Medicine and Department of Microbiology, Kumamoto University School of Medicine</s1><s2>Kumamoto</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>Japon</country><wicri:noRegion>Kumamoto</wicri:noRegion></affiliation></author><author><name sortKey="Maeda, H" sort="Maeda, H" uniqKey="Maeda H" first="H." last="Maeda">H. Maeda</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>First Department of Internal Medicine and Department of Microbiology, Kumamoto University School of Medicine</s1><s2>Kumamoto</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>Japon</country><wicri:noRegion>Kumamoto</wicri:noRegion></affiliation></author><author><name sortKey="Ando, M" sort="Ando, M" uniqKey="Ando M" first="M." last="Ando">M. Ando</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>First Department of Internal Medicine and Department of Microbiology, Kumamoto University School of Medicine</s1><s2>Kumamoto</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>Japon</country><wicri:noRegion>Kumamoto</wicri:noRegion></affiliation></author></analytic><series><title level="j" type="main">American journal of respiratory and critical care medicine</title><title level="j" type="abbreviated">Am. j. respir. crit. care med.</title><idno type="ISSN">1073-449X</idno><imprint><date when="1998">1998</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">American journal of respiratory and critical care medicine</title><title level="j" type="abbreviated">Am. j. respir. crit. care med.</title><idno type="ISSN">1073-449X</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animal</term><term>Animals</term><term>Anti-Bacterial Agents (administration & dosage)</term><term>Anti-Bacterial Agents (therapeutic use)</term><term>Anti-Inflammatory Agents (administration & dosage)</term><term>Anti-Inflammatory Agents (therapeutic use)</term><term>Antiinflammatory agent</term><term>Body Weight</term><term>Bronchoalveolar Lavage Fluid (cytology)</term><term>Cause of Death</term><term>Dose-Response Relationship, Drug</term><term>Erythromycin</term><term>Erythromycin (administration & dosage)</term><term>Erythromycin (therapeutic use)</term><term>Exploration</term><term>Free Radicals (adverse effects)</term><term>Influenza A virus (drug effects)</term><term>Influenzavirus</term><term>Injections, Intraperitoneal</term><term>Interferon-gamma (biosynthesis)</term><term>Interferon-gamma (drug effects)</term><term>Intraperitoneal administration</term><term>Lung (drug effects)</term><term>Lung (enzymology)</term><term>Lung (pathology)</term><term>Lung (virology)</term><term>Lymphocytes (drug effects)</term><term>Lymphocytes (pathology)</term><term>Macrophages (drug effects)</term><term>Macrophages (pathology)</term><term>Male</term><term>Mechanism of action</term><term>Mice</term><term>Mice, Inbred Strains</term><term>Monocytes (drug effects)</term><term>Monocytes (pathology)</term><term>Mouse</term><term>Nitrates (blood)</term><term>Nitric Oxide (adverse effects)</term><term>Nitric Oxide (biosynthesis)</term><term>Nitric Oxide Synthase (drug effects)</term><term>Nitrites (blood)</term><term>Orthomyxoviridae Infections (drug therapy)</term><term>Orthomyxoviridae Infections (enzymology)</term><term>Orthomyxoviridae Infections (pathology)</term><term>Pneumonia</term><term>Pneumonia, Viral (drug therapy)</term><term>Pneumonia, Viral (enzymology)</term><term>Pneumonia, Viral (pathology)</term><term>Superoxides (adverse effects)</term><term>Survival</term><term>Survival Rate</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term><term>Anti-inflammatoires (administration et posologie)</term><term>Anti-inflammatoires (usage thérapeutique)</term><term>Antibactériens (administration et posologie)</term><term>Antibactériens (usage thérapeutique)</term><term>Cause de décès</term><term>Infections à Orthomyxoviridae (anatomopathologie)</term><term>Infections à Orthomyxoviridae (enzymologie)</term><term>Infections à Orthomyxoviridae (traitement médicamenteux)</term><term>Injections péritoneales</term><term>Interféron gamma ()</term><term>Interféron gamma (biosynthèse)</term><term>Lignées consanguines de souris</term><term>Liquide de lavage bronchoalvéolaire (cytologie)</term><term>Lymphocytes ()</term><term>Lymphocytes (anatomopathologie)</term><term>Macrophages ()</term><term>Macrophages (anatomopathologie)</term><term>Monocytes ()</term><term>Monocytes (anatomopathologie)</term><term>Monoxyde d'azote (biosynthèse)</term><term>Monoxyde d'azote (effets indésirables)</term><term>Mâle</term><term>Nitrates (sang)</term><term>Nitric oxide synthase ()</term><term>Nitrites (sang)</term><term>Pneumopathie virale (anatomopathologie)</term><term>Pneumopathie virale (enzymologie)</term><term>Pneumopathie virale (traitement médicamenteux)</term><term>Poids du corps</term><term>Poumon ()</term><term>Poumon (anatomopathologie)</term><term>Poumon (enzymologie)</term><term>Poumon (virologie)</term><term>Radicaux libres (effets indésirables)</term><term>Relation dose-effet des médicaments</term><term>Souris</term><term>Superoxydes (effets indésirables)</term><term>Taux de survie</term><term>Virus de la grippe A ()</term><term>Érythromycine (administration et posologie)</term><term>Érythromycine (usage thérapeutique)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Anti-Bacterial Agents</term><term>Anti-Inflammatory Agents</term><term>Erythromycin</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Free Radicals</term><term>Nitric Oxide</term><term>Superoxides</term></keywords><keywords scheme="MESH" type="chemical" qualifier="biosynthesis" xml:lang="en"><term>Interferon-gamma</term><term>Nitric Oxide</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Nitrates</term><term>Nitrites</term></keywords><keywords scheme="MESH" type="chemical" qualifier="drug effects" xml:lang="en"><term>Interferon-gamma</term><term>Nitric Oxide Synthase</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-Bacterial Agents</term><term>Anti-Inflammatory Agents</term><term>Erythromycin</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Anti-inflammatoires</term><term>Antibactériens</term><term>Érythromycine</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Infections à Orthomyxoviridae</term><term>Lymphocytes</term><term>Macrophages</term><term>Monocytes</term><term>Pneumopathie virale</term><term>Poumon</term></keywords><keywords scheme="MESH" qualifier="biosynthèse" xml:lang="fr"><term>Interféron gamma</term><term>Monoxyde d'azote</term></keywords><keywords scheme="MESH" qualifier="cytologie" xml:lang="fr"><term>Liquide de lavage bronchoalvéolaire</term></keywords><keywords scheme="MESH" qualifier="cytology" xml:lang="en"><term>Bronchoalveolar Lavage Fluid</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Influenza A virus</term><term>Lung</term><term>Lymphocytes</term><term>Macrophages</term><term>Monocytes</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Orthomyxoviridae Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Monoxyde d'azote</term><term>Radicaux libres</term><term>Superoxydes</term></keywords><keywords scheme="MESH" qualifier="enzymologie" xml:lang="fr"><term>Infections à Orthomyxoviridae</term><term>Pneumopathie virale</term><term>Poumon</term></keywords><keywords scheme="MESH" qualifier="enzymology" xml:lang="en"><term>Lung</term><term>Orthomyxoviridae Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Lung</term><term>Lymphocytes</term><term>Macrophages</term><term>Monocytes</term><term>Orthomyxoviridae Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Nitrates</term><term>Nitrites</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à Orthomyxoviridae</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Anti-inflammatoires</term><term>Antibactériens</term><term>Érythromycine</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Poumon</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Lung</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Body Weight</term><term>Cause of Death</term><term>Dose-Response Relationship, Drug</term><term>Injections, Intraperitoneal</term><term>Male</term><term>Mice</term><term>Mice, Inbred Strains</term><term>Survival Rate</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Animaux</term><term>Cause de décès</term><term>Injections péritoneales</term><term>Interféron gamma</term><term>Lignées consanguines de souris</term><term>Lymphocytes</term><term>Macrophages</term><term>Monocytes</term><term>Mâle</term><term>Nitric oxide synthase</term><term>Pneumonie</term><term>Influenzavirus</term><term>Erythromycine</term><term>Poids du corps</term><term>Poumon</term><term>Relation dose-effet des médicaments</term><term>Souris</term><term>Taux de survie</term><term>Virus de la grippe A</term><term>Voie intrapéritonéale</term><term>Antiinflammatoire</term><term>Exploration</term><term>Mécanisme action</term><term>Survie</term><term>Souris</term><term>Animal</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Erythromycin (EM) is an antibiotic with potent antiinflammatory effects that is used for treating chronic lower respiratory tract infections. It has been shown that free radicals, such as the superoxide anion and nitric oxide (NO), are pathogenic molecules in viral disease. Much attention has been given to a critical role of NO in the pathologic events of various inflammatory diseases. In the present study, we evaluated the effects of EM on influenza-virus-induced pneumonia in mice infected with a lethal dose of influenza virus A/Kumamoto/Y5/67 (H2N2). The administration of EM at a dose of 3.3 mg/kg/d (intraperitoneally, from Days 1 to 6 after infection), significantly improved the survival rate of mice infected with influenza virus, and the survival rate of the virus-infected mice at Day 20 after infection increased in a dose-dependent fashion with EM administered to the animals, from 14% among controls to 42% among animals given EM at 1.0 mg/kg/d and 57% among those given EM at 3.3 mg/kg/d. The induction of interferon-γ (IFN-γ) in the mouse lung was inhibited by EM treatment on Day 6 after infection. Simultaneously, the number of inflammatory cells recovered in lung lavage fluid 6 d after virus infection was significantly reduced by the treatment with EM. The EM treatment resulted in a dose-dependent decrease in the level of nitrite/nitrate (metabolites of NO) in the serum and the NO synthase (NOS)-inducting potential in the lungs of the virus-infected mice. These results indicate that EM may have substantial therapeutic value for various acute inflammatory disorders such as influenza-virus-induced pneumonia, by inhibiting inflammatory-cell responses and suppressing NO overproduction in the lung.</div></front></TEI><affiliations><list><country><li>Japon</li></country></list><tree><country name="Japon"><noRegion><name sortKey="Sato, K" sort="Sato, K" uniqKey="Sato K" first="K." last="Sato">K. Sato</name></noRegion><name sortKey="Akaike, T" sort="Akaike, T" uniqKey="Akaike T" first="T." last="Akaike">T. Akaike</name><name sortKey="Ando, M" sort="Ando, M" uniqKey="Ando M" first="M." last="Ando">M. Ando</name><name sortKey="Doi, T" sort="Doi, T" uniqKey="Doi T" first="T." last="Doi">T. Doi</name><name sortKey="Fujii, S" sort="Fujii, S" uniqKey="Fujii S" first="S." last="Fujii">S. Fujii</name><name sortKey="Maeda, H" sort="Maeda, H" uniqKey="Maeda H" first="H." last="Maeda">H. Maeda</name><name sortKey="Muranaka, H" sort="Muranaka, H" uniqKey="Muranaka H" first="H." last="Muranaka">H. Muranaka</name><name sortKey="Suga, M" sort="Suga, M" uniqKey="Suga M" first="M." last="Suga">M. Suga</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001B19 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001B19 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= H2N2V1
|flux= Main
|étape= Exploration
|type= RBID
|clé= Pascal:98-0174340
|texte= Therapeutic effect of erythromycin on influenza virus-induced lung injury in mice
}}
| This area was generated with Dilib version V0.6.33. |  |